The clinical relevance of MOG antibody testing in cerebrospinal fluid

Molly Reynolds, Irene Tan, Kristy Nguyen, Vera Merheb, Fiona X.Z. Lee, Benjamin P. Trewin, Magdalena Lerch, Snehal Shah, Nigel Wolfe, Katherine Buzzard, Jeannette Lechner-Scott, Marzena Fabis-Pedrini, Anthony Fok, Nevin John, Chris Kneebone, Con Yiannikas, David A. Brown, Allan G. Kermode, Stephen Reddel, Russell C. DaleFabienne Brilot, Sudarshini Ramanathan, Robert Adam, Jane Andersen, Ian Andrews, Jayne Antony, Patrick Aouad, Monica Badve, Michael H. Barnett, Joshua Barton, Heidi Beadnall, Stefan Blum, Michael Boggild, Fabienne Brilot, Simon Broadley, David A. Brown, Jim Burrow, Helmut Butzkueven, Katherine Buzzard, Ann Bye, Anita Cairns, Sophie Calvert, Fiona Chan, Shabeed Chelakkadan, Melissa Chu, Damian R. Clark, Isabella Cotter, Russell C. Dale, Fionna Dela Cruz, Sanjay Swaminathan

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
1 Downloads (Pure)

Abstract

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is diagnosed by serum MOG-immunoglobulin G (MOG-IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for MOG-IgG. Only 7/1016 (0.7%) seronegative patients had CSF-restricted MOG-IgG. While 3/7 patients had longitudinally extensive transverse myelitis, four had a confirmed alternate diagnosis (three multiple sclerosis, one CNS vasculitis). In a national referral setting, CSF-restricted MOG-IgG had a low sensitivity (2.63%, 95%CI 0.55-7.50%) and low positive predictive value (1.97%, 95%CI 0.45-8.13%). We strongly recommend serum as the preferred diagnostic biospecimen, and urge caution in the interpretation of CSF-restricted MOG-IgG in patients without clinico-radiological features consistent with MOGAD.
Original languageEnglish
Pages (from-to)2514-2519
Number of pages6
JournalAnnals of Clinical and Translational Neurology
Volume11
Issue number9
DOIs
Publication statusPublished - Sept 2024

Fingerprint

Dive into the research topics of 'The clinical relevance of MOG antibody testing in cerebrospinal fluid'. Together they form a unique fingerprint.

Cite this